Cilostazol in diabetic neuropathy: Premature farewell or new beginning?

Angiology

Volumn 62, Issue 8, 2011, Pages 605-608

  Papanas, N ^a   Maltezos, E ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

cilostazol; diabetes; diabetic neuropathy; ischemia

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CILOSTAZOL; CYCLIC AMP; HYPOCHOLESTEROLEMIC AGENT; LIPID; PLACEBO; RUBOXISTAURIN; URIC ACID;

ARTICLE; BLOOD FLOW; BODY MASS; DIABETIC NEUROPATHY; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVITY; FOLLOW UP; HEART RATE VARIABILITY; HUMAN; LIPID BLOOD LEVEL; LOW DRUG DOSE; NERVE CONDUCTION; NERVE FUNCTION; NERVE REGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCEPTIVE THRESHOLD; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; TREATMENT DURATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; VIBRATION; WALKING;

DIABETIC NEUROPATHIES; HUMANS; PHOSPHODIESTERASE 3 INHIBITORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 80054764035     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711402664     Document Type: Article

References (37)

1. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 ; 33 (10). 2285-2293
2. Sugimoto K, Murakawa Y, Sima AA. Diabetic neuropathy-a continuing enigma. Diabetes Metab Res Rev. 2000 ; 16 (6). 408-433
3. Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev. 2008 ; 24 (suppl 1). S52 - S57
4. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003 ; 26 (5). 1553-1579 (Pubitemid 36934465)
5. Boulton AJ. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes Metab Res Rev. 2008 ; 24 (suppl 1). S3 - S6
6. Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009 ; 301 (15). 1547-1555
7. Dobretsov M, Romanovsky D, Stimers JR. Early diabetic neuropathy: triggers and mechanisms. World J Gastroenterol. 2007 ; 13 (2). 175-191 (Pubitemid 46231321)
8. Pop-Busui R, Low PA, Waberski BH, et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation. 2009 ; 119 (22). 2886-2893
9. Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010 ; 33 (5). 1090-1096
10. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010 ; 376 (9739). 419-430
11. Tesfaye S, Malik R, Harris N, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia. 1996 ; 39 (3). 329-335 (Pubitemid 26066803)
12. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005 ; 352 (4). 341-350
13. Ziegler D, Rathmann W, Dickhaus T, et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008 ; 31 (3). 464-469
14. Chapman TM, Goa KL. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs. 2003 ; 3 (2). 117-138 (Pubitemid 36665531)
15. Naka K, Sasaki H, Kishi Y, et al. Effects of cilostazol on development of experimental diabetic neuropathy: functional and structural studies, and Na+ -K+ -ATPase acidity in peripheral nerve in rats with streptozotocin-induced diabetes. Diabetes Res Clin Pract. 1995 ; 30 (3). 153-162
16. Suh KS, Oh SJ, Woo JT, et al. Effect of cilostazol on the neuropathies of streptozotocin-induced diabetic rats. Korean J Intern Med. 1999 ; 14 (2). 34-40
17. Kihara M, Schmelzer JD, Low PA. Effect of cilostazol on experimental diabetic neuropathy in the rat. Diabetologia. 1995 ; 38 (8). 914-918
18. Uehara K, Sugimoto K, Wada R, et al. Effects of cilostazol on the peripheral nerve function and structure in STZ-induced diabetic rats. J Diabetes Complications. 1997 ; 11 (3). 194-202 (Pubitemid 27243645)
19. Yamamoto Y, Yasuda Y, Kimura Y, Komiya Y. Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats. Eur J Pharmacol. 1998 ; 352 (2-3). 171-178 (Pubitemid 28345115)
20. Okuda Y, Mizutani M, Ikegami T, Ueno E, Yamashita K. Hemodynamic effects of cilostazol on peripheral artery in patients with diabetic neuropathy. Arzneimittelforschung. 1992 ; 42 (4). 540-542
21. Sekiguchi M, Morikawa A, Nakajima K, et al. Clinical usefulness of cilostazol (Pletal) on diabetic neuropathy and serum lipids levels. Jpn Pharmacol Ther. 1991 ; 19 (5). 3273-3277
22. Kimura M. Effects of Pletal on incidence of sensory dysfunctions in diabetics. J New Remedies Clin. 1996 ; 45 (5). 371-376
23. Takei I, Nakamoto S, Ishii M, et al. Cilostazol, a phosphodiesterase inhibitor for the treatment of diabetic neuropathy. Diabetes Res. 1997 ; 32 (3). 19-25
24. Rosales RL, Delgado-Delos Santos MMS, Mercado-Asis LB Angiology. 2011 :
25. Grant I, O'Brien P, Dyck PJ Diabetic Neuropathy. Dyck PJ Thomas PK, ed. Philadelphia: WB Saunders ; 1999: 123-141.
26. McDermott MM, Liu K, Guralnik JM, et al. Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease. J Vasc Surg. 1998 ; 28 (6). 1072-1081 (Pubitemid 28562712)
27. O'Donnell ME, Badger SA, Sharif MA, et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology. 2009 ; 59 (6). 695-704
28. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care. 2002 ; 25 (11). 2048-2052 (Pubitemid 41071067)
29. Tesfaye S, Tandan R, Bastyr EJ 3rd, et al. Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials. Diabetes Care. 2007 ; 30 (10). 2626-2632 (Pubitemid 47547808)
30. Casellini CM, Barlow PM, Rice AL, et al. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care. 2007 ; 30 (4). 896-902 (Pubitemid 46556584)
31. Vinik AI, Bril V, Kempler P, et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther. 2005 ; 27 (8). 1164-1180 (Pubitemid 41393912)
32. Mitsuhashi N, Tanaka Y, Kubo S, et al. Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients. Endocr J. 2004 ; 51 (6). 545-550 (Pubitemid 40209021)
33. Papanas N, Katsiki N, Papatheodorou K, et al Angiology.
34. Papanas N, Ziegler D. New diagnostic tests for diabetic distal symmetric polyneuropathy. J Diabetes Complications. 2011 ; 25 (1). 44-51
35. Mojaddidi M, Quattrini C, Tavakoli M, Malik RA. Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy. Curr Diab Rep. 2005 ; 5 (6). 417-422 (Pubitemid 43020007)
36. Mehra S, Tavakoli M, Kallinikos PA, et al. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care. 2007 ; 30 (10). 2608-2612 (Pubitemid 47547805)
37. Fioretto P, Dodson PM, Ziegler D, Rosenson RS. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol. 2010 ; 6 (1). 19-25